Company profile

Ixchelsis company profile

Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose study in healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health..... For more information, log in to dureach.com to view the full company profile.

Business identity

Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$10K+
Founded
2011-01-01

Headquarters

Headquarters
Kent, Sandwich, United Kingdom
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
2
Total equity funding
$12M
Last funding
Series Unknown / $12M / 2016-12-05
Last equity funding
Series Unknown / $12M
Investors
2
Founders
2

Founders and investors

Founders

Gary MuirheadLiz Littlewood

Investors

Pfizer Venture InvestmentsTVM Capital Life Science

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.